55056 Federal Register / Vol. 74, No. 205 / Monday, October 26, 2009 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Notice of Meeting; National 

Commission on Children and Disasters 

AGENCY: Administration for Children 

and Families, Department of Health and 

Human Services. 

ACTION: Notice of meeting. 

DATES: The meeting will be held on 

Tuesday, November 10, 2009, from 9:30 

a.m. to 3:30 p.m. 

ADDRESSES: The meeting will be held at 

the Administration for Children and 

Families, 901 D Street, SW., 

Washington, DC 20024. To attend either 

in person or via teleconference, please 

register by 5 p.m. Eastern Time, 

November 6, 2009. To register, please email jacqueline.haye@acf.hhs.gov with 

‘‘Meeting Registration’’ in the subject 

line, or call (202) 205–9560. Registration 

must include your name, affiliation, and 

phone number. If you require a sign 

language interpreter or other special 

assistance, please call Jacqueline Haye 

at (202) 205–9560 or e-mail 

jacqueline.haye@acf.hhs.gov as soon as 

possible and no later than 5 p.m. 

Eastern Time, November 2, 2009. 

Agenda: The Commission will 

discuss: (1) The Department of Health 

and Human Services’ efforts to support 

the needs of children in disaster 

situations; (2) the Federal Emergency 

Management Agency’s efforts to support 

the needs of children in disaster 

situations; and (3) plans for future work 

of the Commission. 

Written comments may be submitted 

electronically to 

roberta.lavin@acf.hhs.gov with ‘‘Public 

Comment’’ in the subject line. The 

Commission recommends that you 

include your name, mailing address and 

an e-mail address or other contact 

information in the body of your 

comment. This ensures that you can be 

identified as the submitter of the 

comment, and it allows the Commission 

to contact you if further information on 

the substance of the comment is needed 

or if your comment cannot be read due 

to technical difficulties. The 

Commission’s policy is that the 

Commission will not edit your 

comment, and any identifying or contact 

information provided in the body of a 

comment will be included as part of the 

comment placed in the official record. 

The Commission will provide an 

opportunity for public comments during 

the public meeting on November 10, 

2009. Those wishing to speak will be 

limited to three minutes each; speakers 

are encouraged to submit their remarks 

in writing in advance to ensure their 

comment is received in case there is 

inadequate time for all comments to be 

heard on November 10, 2009. 

Additional Information: Contact 

Roberta Lavin, Office of Human Services 

Emergency Preparedness and Response, 

e-mail roberta.lavin@acf.hhs.gov or 

(202) 401–9306. 

SUPPLEMENTARY INFORMATION: The 

National Commission on Children and 

Disasters is an independent Commission 

that shall conduct a comprehensive 

study to examine and assess the needs 

of children as they relate to preparation 

for, response to, and recovery from all 

hazards, building upon the evaluations 

of other entities and avoiding 

unnecessary duplication by reviewing 

the findings, conclusions, and 

recommendations of these entities. The 

Commission shall then submit a report 

to the President and the Congress on the 

Commission’s independent and specific 

findings, conclusions, and 

recommendations to address the needs 

of children as they relate to preparation 

for, response to, and recovery from all 

hazards, including major disasters and 

emergencies. 

Dated: October 19, 2009. 

Carmen R. Nazario, 

Assistant Secretary for Children and Families. 

[FR Doc. E9–25646 Filed 10–23–09; 8:45 am] 

BILLING CODE 4184–06–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Anti-Infective Drugs Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Anti-Infective 

Drugs Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on December 10, 2009, from 8 a.m. 

to 4:30 p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, The Ballrooms, 620 

Perry Pkwy., Gaithersburg, MD. The 

hotel phone number is 301–977–8900. 

Contact Person: Minh Doan, Center 

for Drug Evaluation and Research (HFD– 

21), Food and Drug Administration, 

5600 Fishers Lane (for express delivery, 

5630 Fishers Lane, rm. 1093), Rockville, 

MD 20857, 301–827–7001, FAX 301– 

827–6776, e-mail: 

minh.doan@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington DC area), code 3014512530. 

Please call the Information Line for upto-date information on this meeting. A 

notice in the Federal Register about last 

minute modifications that impact a 

previously announced advisory 

committee meeting cannot always be 

published quickly enough to provide 

timely notice. Therefore, you should 

always check the agency’s Web site and 

call the appropriate advisory committee 

hot line/phone line to learn about 

possible modifications before coming to 

the meeting. 

Agenda: On December 10, the 

committee will discuss new drug 

application (NDA) 050–814, inhaled 

aztreonam, Gilead Sciences, Inc., for the 

proposed indication of improvement of 

respiratory symptoms and pulmonary 

function in cystic fibrosis patients with 

Pseudomonas aeruginosa, a bacterial 

infection. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before November 25, 2009. 

Oral presentations from the public will 

be scheduled between approximately 1 

p.m. to 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before November 17, 2009. Time 

allotted for each presentation may be 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 74, No. 205 / Monday, October 26, 2009 / Notices 55057 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

November 18, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Minh Doan 

at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: October 20, 2009. 

David Horowitz, 

Assistant Commissioner for Policy. 

[FR Doc. E9–25627 Filed 10–23–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Anti-Infective Drugs Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Anti-Infective 

Drugs Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on December 9, 2009, from 8 a.m. 

to 5 p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, The Ballrooms, 620 

Perry Parkway, Gaithersburg, MD. The 

hotel phone number is 301–977–8000. 

Contact Person: Minh Doan, Center 

for Drug Evaluation and Research (HFD– 

21), Food and Drug Administration, 

5600 Fishers Lane (for express delivery, 

5630 Fishers Lane, rm. 1093) Rockville, 

MD 20857, 301–827–7001, FAX 301– 

827–6776, e-mail: 

minh.doan@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572) in the 

Washington DC area), code 3014512530. 

Please call the Information Line for upto-date information on this meeting. A 

notice in the Federal Register about last 

minute modifications that impact a 

previously announced advisory 

committee meeting cannot always be 

published quickly enough to provide 

timely notice. Therefore, you should 

always check the agency’s Web site and 

call the appropriate advisory committee 

hot line/phone line to learn about 

possible modifications before coming to 

the meeting. 

Agenda: On December 9, 2009, the 

committee will discuss endpoints and 

other clinical trial design issues in the 

development of antibacterial products 

for the treatment of communityacquired bacterial pneumonia. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before November 24, 2009. 

Oral presentations from the public will 

be scheduled between approximately 

1:30 p.m. and 2:30 p.m. Those desiring 

to make formal oral presentations 

should notify the contact person and 

submit a brief statement of the general 

nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, and 

an indication of the approximate time 

requested to make their presentation on 

or before November 16, 2009. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

November 17, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Minh Doan 

at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: October 20, 2009. 

David Horowitz, 

Assistant Commissioner for Policy. 

[FR Doc. E9–25628 Filed 10–23–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

mstockstill on DSKH9S0YB1PROD with NOTICES